Interaction Checker

Prescribing Resources

We have produced various materials in PDF format to aid the use of experimental agents in the treatment of COVID-19.

These resources are freely available and the Liverpool Drug Interactions Group would like to encourage the dissemination (with an appropriate acknowledgement) of this drug-drug interaction information for non-commercial use. If referencing these Prescribing Resources, it is important to include the publication date since these resources are updated as new data come to light. Please cite as: [Prescribing Resource Title], [PDF Publication Date], University of Liverpool, available from www.covid19-druginteractions.org, [accession date].

Prescribing Resources

Evaluating the interaction risk of COVID-19 therapies.

Updated November 2022

Assessing a patient for treatment with Paxlovid

Updated November 2022

Interactions with selected outpatient medicines and Paxlovid

Updated September 2022

Interactions with selected WHO Essential Medicines and Paxlovid

Updated September 2022

Guidance for Paxlovid dosing in patients with renal disease and patients on dialysis

Updated June 2022

Guidance for resuming paused or dose-adjusted comedications with Paxlovid

Updated May 2022

Administering Paxlovid as crushed tablets

Updated November 2022

"Treatment Selector" for Key COVID-19 Therapies

Updated September 2022

At-a-glance summary of interactions with COVID-19 antiviral therapies.

Updated September 2022

At-a-glance summary of interactions with COVID-19 host-directed therapies.

Updated September 2022

Administration in cases of swallowing difficulties.

Updated November 2022

Dose recommendations for patients with renal impairment

Updated September 2022

Dose recommendations for patients with hepatic impairment

Updated July 2022
Academic Sponsors / Collaborators
Editorial Sponsors / Research Funders